Clinical trials

6

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers

This is a single dose, randomized, open-label, two-way crossover study to investigate the food-effect bioavailability of the fixed-dose combination of Gemigliptin/Dapagliflozin/Metformin 50/10/1000 mg in healthy volunteers under fasting and fed conditions.

Participants needed: 28
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: LG ChemUpdated: Apr 13, 2026Locations: 1
Eligibility criteria

Healthy Thai male and female subjects between the ages of 18 to 55 years. [+6]

History of allergic reaction or hypersensitivity to gemigliptin or dapagliflozin... [+6]

Status: Recruiting

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109 as monotherapy in participants with advanced and/or metastatic non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), urothelial carcinoma, or malignant melanoma and no available standard of care treatment options, and as combination therapy with atezolizumab in participants with advanced and/or metastatic NSCLC.

Participants needed: 76
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: LG ChemUpdated: Nov 24, 2025Locations: 1
Eligibility criteria

Age ≥18 years old at the time of signing the ICF. [+8]

Clinically significant cardiac disease or cardiac failure. [+10]

Status: Recruiting

A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

The purpose of this study is to evaluate immunogenicity, safety and lot-to-lot consistency of LBVD in comparison to co-administration of Pentavalent vaccine and Poliomyelitis Vaccine (Inactivated) in separate injections at four weeks after completion of three-dose primary series at 6-10-14 weeks of age when administered to healthy infants

Participants needed: 1,186
Trial details
Phase: Phase 2, Phase 3Age: 6-8Biological sex: AllType: InterventionalSponsor: LG ChemUpdated: Jul 3, 2025Locations: 1
Eligibility criteria

healthy infants from 6 weeks to 8 weeks of age (both inclusive) [+3]

Known history of Hib infection, HepB, diphtheria, tetanus, pertussis, or poliomy... [+10]

Status: Recruiting

Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulation in Infertile Women Undergoing in Vitro Fertilization-embryo Transfer (IVF-ET).

The aim of this randomized, open-label, active-controlled, parallel-group, multicenter, phase IV study is to assess the efficacy and safety of Fang Le Shu versus Guo Na Fen used for controlled ovarian stimulation in infertile women undergoing In Vitro Fertilization-Embryo Transfer.

Participants needed: 248
Trial details
Phase: Phase 4Age: 20-39Biological sex: FemaleType: InterventionalSponsor: LG ChemUpdated: Apr 10, 2025Locations: 1
Eligibility criteria

Is pre-menopausal female aged ≥20 to <40 years. [+4]

Has any known clinically significant major systemic disease, or endocrine or met... [+11]

Status: Not yet recruiting

Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age

This is a phase II, randomized, double-blind, active-controlled, parallel-group, multicenter study to evaluate the immunogenicity and safety of DTaP-HepB-IPV-Hib hexavalent vaccine LR20062 in healthy infants as primary series at 2, 4, 6 months of age.

Participants needed: 336
Trial details
Phase: Phase 2Age: 50-70Biological sex: AllType: InterventionalSponsor: LG ChemUpdated: Oct 1, 2024
Eligibility criteria

Is male or female aged two months (50 to 70 days inclusive) on the day of the fi... [+1]

Has a history of diphtheria, tetanus, pertussis, poliovirus, Hep B, or Hib infec... [+9]

Status: Recruiting

Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children

The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj./Eutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).

Participants needed: 6,000
Trial details
Age: 2+Biological sex: AllType: ObservationalSponsor: LG ChemUpdated: Feb 21, 2021Locations: 1
Eligibility criteria

short stature children aged 2 years or more [+2]